S100A6通过招募和活化巨噬细胞促进血管形成*

目的:探讨S100A6经由巨噬细胞介导的促血管生成作用及机制。方法:(1)用重组蛋白 GST-hS100A6处理巨噬细胞后:①收集上清制备条件培养基(简称A6-Mφ-CM),并用之重悬人脐静脉内皮细胞(HUVEC),用体外血管形成试验检测各处理因素对血管形成的影响;②分别用实时荧光定量PCR和Western blot检测巨噬细胞的M2型标志物CD163及促血管形成因子CCL2、IL-6、VEGFA的mRNA和蛋白质水平,以及JAK2和STAT3的蛋白质及其磷酸化水平;③用Transwell迁移试验检测巨噬细胞迁移能力的变化。(2)使用JAK2抑制剂(XL019)预处理巨噬细胞后再加GST-hS100A6处理,检测S100A6促巨噬细胞迁移作用的变化。以重组蛋白GST为实验对照。 结果:(1)A6-Mφ-CM组的血管分支数和血管分支长度既明显高于GST-Mφ-CM组(P值均小于0.05),也明显高于GST-hS100A6直接处理的HUVEC组(P<0.001,P<0.01),提示S100A6处理后的巨噬细胞具有促进血管形成的作用;(2)GST-hS100A6处理后的巨噬细胞中,CD163、CCL2、IL-6、VEGFA的mRNA和蛋白质水平明显高于GST组(P值均小于0.05),提示S100A6诱导巨噬细胞向促血管表型(pro-angiogenic phenotype)转化;(3)GST-hS100A6处理后,巨噬细胞的迁移数是GST组的1.4倍(P<0.01),提示S100A6具有招募巨噬细胞的作用;(4)GST-hS100A6处理组巨噬细胞的JAK2和STAT3的蛋白质及其磷酸化水平都明显高于GST组(P值均小于0.05),而JAK2抑制剂XL019可部分抑制S100A6促进巨噬细胞迁移的作用(P<0.01),提示S100A6促进巨噬细胞迁移作用机制涉及JAK2/STAT3信号通路的激活。 结论:微环境中的S100A6可通过招募巨噬细胞并进一步诱导其向促血管表型转化,进而促进新生血管形成;其招募巨噬细胞的机制涉及JAK2/STAT3信号通路的激活。     

S100A9参与介导具核梭杆菌促结肠癌细胞的增殖与迁移的作用

目的:探讨S100A9在具核梭杆菌(Fusobacterium nucleatum,Fn)促结肠癌HCT116和SW480细胞增殖与迁移中的作用。方法:Fn感染HCT116和SW480细胞后,分别采用CCK8实验及Transwell实验检测结肠癌细胞的增殖及迁移能力的变化,采用Real time PCR及Western blot分别检测S100A9基因及蛋白质水平的变化;用S100A9 siRNA转染HCT116和SW480细胞后感染Fn,采用CCK8实验及Transwell实验分别检测两株细胞增殖及迁移能力的变化;利用NF-κB抑制剂BAY 11-7082预处理HCT116和SW480细胞后再感染Fn,采用Real time PCR及Western blot分别检测S100A9基因及蛋白质水平的变化。结果:(1) Fn可促进HCT116和SW480细胞增殖及迁移(P 0.001);(2) Fn感染的HCT116和SW480细胞中S100A9基因及蛋白质水平均较相应对照组明显升高,差异均具有高度显著性(P 0. 01或P 0. 001),即Fn上调S100A9的表达;(3)用S100A9 siRNA下调HCT116和SW480细胞中S100A9表达后,Fn促进这两株细胞增殖及迁移的作用则明显减弱,差异均具有高度显著性(P 0. 001),表明S100A9参与介导Fn的促HCT116和SW480细胞增殖及迁移的作用;(4)在NF-κB通路抑制剂BAY 11-7082预处理的HCT116和SW480细胞组,Fn上调S100A9基因及蛋白质水平的作用明显被逆转,差异均具有高度显著性(P 0. 01或P 0. 001),表明激活NF-κB转录活性是Fn上调S100A9的机制之一。结论:Fn可上调S100A9表达且与NF-κB活化有关,上调S100A9是Fn促结肠癌细胞增殖及迁移的机制之一。     

人骨髓瘤细胞中两条IL-6信号转导途径的相互调控方式

首先利用凝胶阻滞电泳 ( electrophoretic mobility shift assay,EMSA )和免疫沉淀( immunoprecipitation,IP)方法观察两条 IL- 6信号转导途径—— JAK/STAT和 Ras/NF- IL- 6在人骨髓瘤细胞系 Sko- 0 0 7中的诱导激活状态 ;继而采用分别作用于两条途径的蛋白激酶抑制剂或激动剂以及转录因子的反义核酸与 IL- 6共同作用 Sko- 0 0 7细胞 ,观察一条途径激活信号上调 (或下调 )时 ,另外一条途径活化状态的变化 .结果显示 :1 .JAK/STAT和 Ras/NF- IL- 6信号转导途径都能够在 Sko- 0 0 7细胞中诱导激活 ;2 .与 JAK/STAT途径活化相关的某个酪氨酸磷酸化作用参与了Ras途径的诱导激活 ;Ras途径可通过蛋白激酶 MAPK( motigen- activated protein kinase)对 JAK/STAT途径的激活起正调控作用 .这说明在人骨髓瘤细胞 Sko- 0 0 7中两条 IL- 6信号途径可相互调控彼此的活化 .     

S100A9参与介导具核梭杆菌促结肠癌细胞的增殖与迁移的作用 *

目的:探讨S100A9在具核梭杆菌(Fusobacterium nucleatum,Fn)促结肠癌HCT116和SW480细胞增殖与迁移中的作用。方法:Fn感染HCT116和SW480细胞后,分别采用CCK8实验及Transwell实验检测结肠癌细胞的增殖及迁移能力的变化,采用Real time PCR及Western blot分别检测S100A9基因及蛋白质水平的变化;用S100A9 siRNA转染HCT116和SW480细胞后感染Fn,采用CCK8实验及Transwell实验分别检测两株细胞增殖及迁移能力的变化;利用NF-κB抑制剂BAY 11-7082预处理HCT116和SW480细胞后再感染Fn,采用Real time PCR及Western blot分别检测S100A9基因及蛋白质水平的变化。结果:(1)Fn可促进HCT116和SW480细胞增殖及迁移(P<0.001); (2)Fn感染的HCT116和SW480细胞中S100A9基因及蛋白质水平均较相应对照组明显升高,差异均具有高度显著性(P<0.01或P<0.001),即Fn上调S100A9的表达;(3)用S100A9 siRNA下调HCT116和SW480细胞中S100A9表达后,Fn促进这两株细胞增殖及迁移的作用则明显减弱,差异均具有高度显著性(P<0.001),表明S100A9参与介导Fn的促HCT116和SW480细胞增殖及迁移的作用; (4)在NF-κB通路抑制剂BAY 11-7082预处理的HCT116和SW480细胞组,Fn上调S100A9基因及蛋白质水平的作用明显被逆转,差异均具有高度显著性(P<0.01或P<0.001),表明激活NF-κB转录活性是Fn上调S100A9的机制之一。结论:Fn可上调S100A9表达且与NF-κB活化有关,上调S100A9是Fn促结肠癌细胞增殖及迁移的机制之一。     

重组人S100A6促进人乳腺癌细胞MCF-7的增殖和迁移侵袭并抑制其凋亡

该研究旨在探讨重组人S100A6蛋白对乳腺癌细胞株MCF-7的增殖、凋亡、迁移及侵袭能力的影响。利用原核表达制备重组人S100A6蛋白(GST-hS100A6),SDS-PAGE显示其大小为36 kDa,Western blot显示其可以被S100A6抗体特异识别,BCA法测定1 L菌液共收获约16.7 mg蛋白;将其作用于人乳腺癌细胞MCF-7,MTT显示细胞培养48 h时,浓度为100μg/mL和300μg/mL的GST-hS100A6组的D_(492)值较GST组增加29.1%和84.6%(P<0.05),提示S100A6促进MCF-7细胞增殖;平板克隆形成实验显示GST-hS100A6组的克隆形成率较GST组高38.7%(P<0.05),提示S100A6促进MCF-7的克隆形成;Hoechst染色显示GST-hS100A6组在24 h时细胞凋亡率较GST组减少67.8%(P<0.05),48 h时细胞凋亡率较GST组减少58.4%(P<0.05),提示S100A6抑制MCF-7细胞凋亡;划痕实验显示在24 h时GST-hS100A6组的划痕愈合率为GST组的2.2倍(P<0.05),提示S100A6促...     

X射线对A549细胞DNA的损伤可能与JAK/STAT信号通路的激活有关

本研究旨在观察不同剂量X射线对A549细胞DNA的损伤和JAK/STAT信号通路激活水平之间的关系。分别用2、4、8Gy X射线对A549细胞进行照射后,用CCK8法检测A549细胞增殖情况,用酶联免疫法检测照射后不同时间点培养液上清中白介素6 (interleukin 6, IL-6)的含量,用免疫荧光染色法检测细胞IL-6受体(IL-6 receptor, IL-6R)和p53结合蛋白1 (p53 binding protein 1, 53BP1)的蛋白表达情况,用Western blot检测细胞JAK2、p-JAK2、STAT3和p-STAT3的蛋白表达水平。结果显示,和对照组相比,X射线照射可降低细胞增殖水平,上调53BP1表达,提高细胞培养液上清中IL-6含量,并上调IL-6R、JAK2、p-JAK2、STAT3和p-STAT3表达水平。X射线照射的上述作用存在一定的剂量依赖性。以上结果提示,X射线造成细胞DNA损伤的机制可能与JAK/STAT信号通路的激活有关。     

抑瘤素M受体对慢性自身免疫性荨麻疹发病机制的影响

本研究旨在探讨抑瘤素M受体(OSMR)在慢性自身免疫性荨麻疹(CAU)发病机制中的作用。本研究分别检测30例CAU患者及30名健康受试者的皮肤组织中OSMR、JAK和STAT3的表达,研究显示OSMR、JAK和STAT3在CAU患者皮肤组织中高表达(p<0.05)。转染OSMR-siRNA可显著降低CAU模型小鼠血清炎症因子IL-1、IL-6和IFN-γ水平,而转染JAK/STAT3信号通路激动剂Tyr705则可显著升高炎症因子水平(p<0.05)。转染OSMR-siRNA可显著降低CAU小鼠瘙痒次数、瘙痒时间和嗜酸性粒细胞计数,而转染Tyr705则可显著升高CAU小鼠瘙痒次数、瘙痒时间和嗜酸性粒细胞计数(p<0.05)。转染OSMR-siRNA促进了CAU小鼠上皮细胞的增殖能力,并抑制了细胞凋亡(p<0.05)。而转染Tyr705则抑制了CAU小鼠上皮细胞的增殖能力,并促进了细胞凋亡(p<0.05)。转染OSMR-siRNA下调了上皮细胞中OSMR、JAK和STAT3的表达,而转染Tyr705则上调了OSMR、JAK和STAT3的表达(p<0.05)。总之,本研究表明OSMR基因在CAU患者皮肤组织中高表达。OSMR基因沉默可通过抑制JAK/STAT3信号通路来抑制炎症因子表达及嗜酸性粒细胞数量,促进上皮细胞增殖并抑制细胞凋亡。     

Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice

Transgenic mice carrying human IL-6 cDNA fused with a murine major histocompatibility class-I promoter (H-2L(d)) were serially administered with anti-interleukin-6 receptor (IL-6R) monoclonal antibody (mAb), MR16-1, from the age of 4 weeks to estimate its efficacy on a variety of disorders developed in these mice, most of which are similar to the disorders associated with Castleman's disease. In the control mice treated with isotype-matched mAb, a massive and multiple IgG1 plasmacytosis, mesangial proliferative glomerulonephritis, leukocytosis, thrombocytosis, anemia and abnormalities of blood chemical parameters have developed in accordance with the elevation of serum IL-6, and 50% of mice have died of renal failure by 18 weeks of age. In contrast, the treatment with MR16-1 prevented all these symptoms and prolonged the lifetime of the majority of the mice. Thus, the constitutive overexpression of IL-6 caused various disorders, and the treatment with anti-IL-6R mAb completely prevented from these symptoms. These results clearly confirm that IL-6 indeed plays an essential role in the pathogenesis of a variety of disorders. Furthermore, anti-IL-6R mAb could provide novel therapy for Castleman's disease and MR16-1 should be a useful tool to estimate therapeutic potential of IL-6 antagonists in a variety of murine models for human disease.     

Facile synthesis of 6-amino-6-deoxycellulose

6-Amino-6-deoxycellulose (4) was synthesized from cellulose by three reaction steps, namely bromination at C-6, displacement of bromine by azide ion, and reduction of the azide group to amino group, in 67% overall yield. The 13C NMR spectrum of compound 4 supports the expected structure for 6-amino-6-deoxycellulose. The degree of substitution of compound 4 was 0.96.     

多发性骨髓瘤与白细胞介素-6

白细胞介素-6是多发性骨髓瘤(multiple myeloma,MM)瘤细胞生长和生存的关键因子,也是MM患者发病的主要因子。IL-6/IL-6R系统通过不同通路影响多发性骨髓瘤瘤细胞生长并导致患者骨损害、类风湿性关节炎等一系列并发症。针对IL-6/IL-6R系统的治疗方法将给MM的治疗带来重大的进展。     

Possible involvement of NADPH requirement in regulation of Glucose-6-Phosphate and 6-Phosphogluconate dehydrogenase levels in rat liver

Summary Previous studies examining regulation of synthesis of Glucose-6-Phosphate and 6-Phosphogluconate dehydrogenase in rat liver have focussed on the induction of these enzymes by different diets and some hormones. However, the precise mechanism regulating increases in the activities of these enzymes is unknown and the factors involved remain unidentified. Considering that many of these metabolic conditions occur simultaneously with the increase of some NADPH consuming pathway, in particular fatty acid synthesis, we suggest that the activities of Glucose-6-Phosphate and 6-Phosphogluconate dehydrogenase could be regulated through a mechanism involving changes in the NADPH requirement. Here, we have studied the effect of changes in the flux through different NADPH consuming pathways on the NADPH/NADP ratio and on Glucose-6-Phosphate and 6-Phosphogluconate levels. The results show that: i) an increase in consumption of NADPH, caused by activation of fatty acid synthesis or the detoxification system which consumes NADPH, is paralleled by an increase in levels of these enzymes; ii) when increase in consumption of NADPH is prevented, Glucose-6-Phosphate and 6-Phosphogluconate dehydrogenase levels do not change.Abbreviations G6PDH Glucose-6-Phosphate Dehydrogenase - 6PGDH 6-Phosphogluconate Dehydrogenase - ME Malic Enzyme - NF Nitrofurantoin - CumOOH Cumene Hydroperoxide - t-BHP t-Butyl hydroperoxide - BCNU 1,3,-Bis (2-chloroethyl)-1-nitrosourea - GR Glutathione Dehydrogenase - 2-ME 2-Mercaptoethanol - DTT Dithiothreitol - NADP B-Nicotinamide-Adenine Dinucleotide Phosphate - NADPH B-Nicotinamide-Adenine Dinucleotide Phosphate Reduced - EDTA Ethylenediaminetetraacetic Acid - GSH Glutathione Reduced Form - GSSG Glutathione Oxidized Form     

Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination

In cancer, mucins are aberrantly O-glycosylated, and consequently, they express tumor-associated antigens such as the Tn determinant (alpha-GalNAc-O-Ser/Thr). As compared with normal tissues, they also exhibit a different pattern of expression. In particular, MUC6, which is normally expressed only in gastric tissues, has been detected in intestinal, pulmonary, colorectal, and breast carcinomas. Recently, we have shown that the MCF7 breast cancer cell line expresses MUC6-Tn glycoproteins in vivo. Cancer-associated mucins show antigenic differences from normal mucins, and as such, they may be used as potential targets for immunotherapy. To develop anticancer vaccines based on the Tn antigen, we prepared several MUC6-Tn glycoconjugates. To this end, we performed the GalNAc enzymatic transfer to two recombinant MUC6 proteins expressed in Escherichia coli, using UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts), which catalyze in vivo the Tn antigen synthesis. We used either a mixture of ppGalNAc-Ts from MCF7 breast cancer cell extracts or a recombinant ppGalNAc-T1. In both cases, we achieved the synthesis of MUC6-Tn glycoconjugates at a semi-preparative scale (mg amounts). These glycoproteins displayed a high level of Tn antigens, although the overall density depends on both enzyme source and protein acceptor. These MUC6-Tn glycoconjugates were recognized by two anti-Tn monoclonal antibodies that are specific to human cancer cells. Moreover, the MUC6-Tn glycoconjugate glycosylated using MCF7 extracts as the ppGalNAc-T source was able to induce immunoglobulin G (IgG) antibodies that recognized a human tumor cell line. In conclusion, the large-scaled production of MUC6 with tumor-relevant glycoforms holds considerable promise for developing effective anticancer vaccines, and further studies of their immunological properties are warranted.     

Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis

In order to assess the potential role of IL-6 in rheumatoid arthritis (RA), we have compared IL-6 deficient (IL-6 ko) mice and their wild-type (wt) counterpart for the capacity to develop methylated bovine serum albumin (mBSA)-induced arthritis. Our data show that IL-6 ko mice are not susceptible to antigen-induced arthritis (AIA). In fact, IL-6 ko mice treated by a standard protocol of immunization with mBSA did not develop joint swelling following intra-articular mBSA injection, nor revealed the characteristic joint lesions by histological examination. Conversely, wt mice treated according to the same protocol developed arthritis about 9 days after intra-articular injection, as detected by knee joint swelling and histological confirmation. We observed that the proliferative response of splenocytes to mBSA was impaired in ko mice following arthritis induction, as compared to the strong response observed in wt mice. Furthermore, anti-mBSA IgG levels were lower in ko mice as compared to wt mice. Finally, we show that sensitivity to AIA can be reconstituted in ko mice by subcutaneous injections of recombinant human IL-6 (rhIL-6). In addition, co-administration of IL-6 with mBSA by intra-articular injection into the joint was only partially effective in conferring sensitivity to AIA, suggesting the importance of a systemic effct for IL-6, but also that an additional role for this cytokine can be envisaged in the local inflammatory reaction during establishment of AIA.     

靶向人白介素-6蛋白的治疗性单克隆抗体研究进展*

白介素-6(interleukin-6,IL-6)作为一种多效的细胞因子,参与机体内众多生理与病理过程。研究表明,IL-6首先与自身受体(IL-6R、gp130)形成异源六聚体复合物,进而激活下游信号转导通路,最终发挥生物学功能。 IL-6信号通路异常活化及功能失调与多种疾病密切相关,如自身免疫疾病、慢性炎症、恶性肿瘤等。另外IL-6的异常表达在新型冠状病毒肺炎(COVID-19)细胞因子风暴综合征(CSS)中也扮演重要角色。一般而言,阻断IL-6信号通路上的各关键节点,均可用于IL-6相关疾病的治疗。有别于阻断IL-6R或gp130等公共受体分子,阻断IL-6蛋白的治疗性单克隆抗体特异性更高,在临床研究中,部分品种显示出其独有的治疗特点及有益的疗效。现阶段只有1个靶向IL-6蛋白的单克隆抗体药物获美国FDA批准上市,以及超过8个治疗性单克隆抗体在临床研究阶段。重点对国内外靶向人IL-6蛋白的治疗性单克隆抗体及其临床应用进行综述。     

The application of microwave heating to the synthesis of 6-amino-6-deoxycellulose

Microwave heating was applied to the reactions involved in the synthesis of 6-amino-6-deoxycellulose, 4. These included, cellulose solubilization, bromination at C-6, displacement of bromine with azide ion, and reduction of the azido group to an amino group. Compared to conventional heating, this approach had the advantages of shortening reaction times and retaining the degree of polymerization of 4.